4 reports of this reaction
2.0% of all GUAIFENESIN, DEXTROMETHORPHAN HBR reports
#11 most reported adverse reaction
NASOPHARYNGITIS is the #11 most commonly reported adverse reaction for GUAIFENESIN, DEXTROMETHORPHAN HBR, manufactured by CVS Pharmacy. There are 4 FDA adverse event reports linking GUAIFENESIN, DEXTROMETHORPHAN HBR to NASOPHARYNGITIS. This represents approximately 2.0% of all 199 adverse event reports for this drug.
Patients taking GUAIFENESIN, DEXTROMETHORPHAN HBR who experience nasopharyngitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NASOPHARYNGITIS is a less commonly reported adverse event for GUAIFENESIN, DEXTROMETHORPHAN HBR, but still significant enough to appear in the safety profile.
In addition to nasopharyngitis, the following adverse reactions have been reported for GUAIFENESIN, DEXTROMETHORPHAN HBR:
The following drugs have also been linked to nasopharyngitis in FDA adverse event reports:
NASOPHARYNGITIS has been reported as an adverse event in 4 FDA reports for GUAIFENESIN, DEXTROMETHORPHAN HBR. This does not prove causation, but indicates an association observed in post-market surveillance data.
NASOPHARYNGITIS accounts for approximately 2.0% of all adverse event reports for GUAIFENESIN, DEXTROMETHORPHAN HBR, making it a notable side effect.
If you experience nasopharyngitis while taking GUAIFENESIN, DEXTROMETHORPHAN HBR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.